Patients with advanced gynecologic malignancies were randomized to receive either carboplatin ( AUC 6 ) , followed by paclitaxel ( 175 mg/m ( 2 ) over 3 h ) ( C-P ) , or the same doses of the agents delivered in the opposite sequence ( P-C ) .
